Life Science Investing CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Life Science Investing CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer Annual Meeting
Life Science Investing CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
Brunswick Exploration Announces Inferred Mineral Resource of 52.2Mt at 1.08% Li2O at Mirage with Additional Exploration Target
